Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men

BJU International

Volumn 108, Issue 1, 2011, Pages 44-48

  Tang, Ping ^a   Sun, Leon ^a   Uhlman, Matthew A ^a   Robertson, Cary N ^a   Polascik, Thomas J ^a   Moul, Judd W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

age; mortality; prostate cancer; prostate specific antigen velocity; risk

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLOW UP; FRAIL ELDERLY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; VELOCITY;

AGED; EARLY DETECTION OF CANCER; EPIDEMIOLOGIC METHODS; HUMANS; MALE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; UNNECESSARY PROCEDURES;

EID: 79959306151     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09812.x     Document Type: Article

References (24)

1. Schroder FH, Hugosson J, Roobol MJ, et al,. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8
2. Andriole GL, Grubb RL 3rd, Buys SS, et al,. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-9
3. Walter LC, Bertenthal D, Lindquist K, Konety BR,. PSA screening among elderly men with limited life expectancies. JAMA 2006; 296: 2336-42 (Pubitemid 44749361)
4. Scales CD Jr, Curtis LH, Norris RD, Schulman KA, Albala DM, Moul JW,. Prostate specific antigen testing in men older than 75 years in. the United States J Urol 2006; 176: 511-4 (Pubitemid 43949407)
5. Cooperberg MR, Konety BR,. Management of localized prostate cancer in men over 65 years. Curr Opin Urol 2009; 19: 309-14
6. Konety BR, Cowan JE, Carroll PR,. Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE. J Urol 2008; 179: 1797-803; discussion 803
7. U.S. Preventative Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149: 185-91
8. Walter LC, Covinsky KE,. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001; 285: 2750-6 (Pubitemid 32525372)
9. Schaeffer EM, Carter HB, Kettermann A, et al,. Prostate specific antigen testing among the elderly-when to stop? J Urol 2009; 181: 1606-14; discussion 13-4
10. Tang P, Sun L, Uhlman MA, et al,. Prostate-specific antigen-based risk-adapted discontinuation of prostate cancer screening in elderly African American and Caucasian American men. Urology 2009; Dec 24 [Epub ahead of print]
11. D'Amico AV, Chen MH, Roehl KA, Catalona WJ,. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351: 125-35
12. D'Amico AV, Renshaw AA, Sussman B, Chen MH,. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005; 294: 440-7 (Pubitemid 41124176)
13. Carter HB, Ferrucci L, Kettermann A, et al,. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006; 98: 1521-7 (Pubitemid 44680903)
14. D'Amico AV, Whittington R, Malkowicz SB, et al,. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74 (Pubitemid 28445094)
15. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul JW,. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 1996; 335: 304-10 (Pubitemid 26362377)
16. Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ, Carter HB,. PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. Eur Urol 2008; 54: 1073-80
17. Ulmert D, Serio AM, O'Brien MF, et al,. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol 2008; 26: 835-41 (Pubitemid 351398073)
18. Etzioni RD, Ankerst DP, Thompson IM,. Re: detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2007; 99: 489-90; author reply 90 (Pubitemid 47073572)
19. Palma D, Tyldesley S, Pickles T,. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy. Cancer 2008; 112: 1941-8 (Pubitemid 351574069)
20. Patel DA, Presti JC, Jr, McNeal JE, Gill H, Brooks JD, King CR,. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol 2005; 23: 6157-62
21. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006; 98: 529-34 (Pubitemid 43898816)
22. Wolters T, Roobol MJ, Bangma CH, Schroder FH,. Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European randomized study of screening for prostate cancer (rotterdam). Eur Urol 2009; 55: 385-92
23. Moul JW, Sun L, Hotaling JM, et al,. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol 2007; 177: 499-503; discussion-4
24. Schroder FH, Roobol-Bouts M, Vis AN, van der Kwast T, Kranse R,. Prostate-specific antigen-based early detection of prostate cancer-validation of screening without rectal examination. Urology 2001; 57: 83-90 (Pubitemid 32065825)